You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/66591
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBalbi, André Luis-
dc.contributor.authorBarbosa, R. A.-
dc.contributor.authorLima, M. C.-
dc.contributor.authorAlmeida, D. B.-
dc.date.accessioned2014-05-27T11:20:18Z-
dc.date.accessioned2016-10-25T18:17:12Z-
dc.date.available2014-05-27T11:20:18Z-
dc.date.available2016-10-25T18:17:12Z-
dc.date.issued2001-10-01-
dc.identifierhttp://dx.doi.org/10.1590/S0104-42302001000400031-
dc.identifier.citationRevista da Associacao Medica Brasileira (1992), v. 47, n. 4, p. 296-301, 2001.-
dc.identifier.issn0104-4230-
dc.identifier.urihttp://hdl.handle.net/11449/66591-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/66591-
dc.description.abstractPURPOSE: To evaluate the therapeutic complications due to the use of immunosupressors in patients with nephropathy. METHODS: 76 patients who had used steroids and cyclophosphamide were retrospectively studied. The cases were divided into three groups: G1= 15 patients with Systemic Lupus Erythematosus without renal lesion; G2= 33 patients with lupus nephritis and G3= 28 patients with nephrotic syndrome owing to idiopathic glomerulopathy. RESULTS: There were no differences related to time of follow up (G1= 42.4 +/- 51, G2= 52.3 +/- 51, G3= 41.8 +/- 47.8 months), total used dosage of steroids (G1= 20, G2= 28, G3= 16 grams) and time of drug use (G1= 20, G2= 26, G3= 14.5 months). About cyclophosphamide use, there was no difference in the percentage of patients who used it (13% in G1, 51% in G2, 28% in G3), but the patients from G1 received lower total dosage than those from G2 (p<0.05). Cushingoid appearance, epigastric distress, psychiatric disorders, diabetes mellitus and ocular alterations occurred in all the three groups, with no statistically significant differences. The infections complications, those considered more severe clinically, were more frequent in G2 (G1= 6%, G2= 15%, G3= 0% - p<0.05), the same occurring with the deaths (7% in G1, 30% in G2, 0% in G3 - p<0.05). CONCLUSION: In patients with lupus nephritis there were more infections complications owing to prolonged immunosuppresion what may indicate a severity marker of this type of lesion.en
dc.format.extent296-301-
dc.language.isopor-
dc.sourceScopus-
dc.subjectcorticosteroid-
dc.subjectcyclophosphamide-
dc.subjectimmunosuppressive agent-
dc.subjectmethylprednisolone-
dc.subjectprednisone-
dc.subjectadult-
dc.subjectcomparative study-
dc.subjectfemale-
dc.subjectfollow up-
dc.subjecthuman-
dc.subjectlupus erythematosus nephritis-
dc.subjectmale-
dc.subjectnephrotic syndrome-
dc.subjectretrospective study-
dc.subjectsystemic lupus erythematosus-
dc.subjectAdrenal Cortex Hormones-
dc.subjectAdult-
dc.subjectCyclophosphamide-
dc.subjectFemale-
dc.subjectFollow-Up Studies-
dc.subjectHumans-
dc.subjectImmunosuppressive Agents-
dc.subjectLupus Erythematosus, Systemic-
dc.subjectLupus Nephritis-
dc.subjectMale-
dc.subjectMethylprednisolone-
dc.subjectNephrotic Syndrome-
dc.subjectPrednisone-
dc.subjectRetrospective Studies-
dc.titleEstudo comparativo das complicações terapêuticas no Lúpus Eritematoso Sistêmico e nas glomerulopatias idiopáticas.pt
dc.title.alternativeA comparative study of therapeutic complications in Systemic Lupus Erythematosus and in idiopathic glomerulopathyen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.identifier.doi10.1590/S0104-42302001000400031-
dc.identifier.scieloS0104-42302001000400031-
dc.rights.accessRightsAcesso aberto-
dc.identifier.file2-s2.0-0035495938.pdf-
dc.relation.ispartofRevista da Associação Médica Brasileira (1992)-
dc.identifier.scopus2-s2.0-0035495938-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.